Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease.
N Domloge-Hultsch, … , W G Carter, K B Yancey
N Domloge-Hultsch, … , W G Carter, K B Yancey
Published October 1, 1992
Citation Information: J Clin Invest. 1992;90(4):1628-1633. https://doi.org/10.1172/JCI116033.
View: Text | PDF
Research Article Article has an altmetric score of 12

Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease.

  • Text
  • PDF
Abstract

Epiligrin, the major component of human keratinocyte extracellular matrix, serves as the preferred integrin ligand for alpha 3 beta 1 in plasma membranes and focal adhesions, and colocalizes with alpha 6 beta 4 in hemidesmosomes. In human skin, epiligrin is found in the lamina lucida subregion of epidermal basement membrane, where it is thought to be associated with anchoring filaments. We have identified three patients with an acquired mucosal predominant subepidermal blistering disease who have IgG anti-basement membrane autoantibodies that bind the lamina lucida/lamina densa interface of epidermal basement membrane, stain cultured human keratinocyte extracellular matrix, and immunoprecipitate disulfide linked polypeptides of 170, 145, 125, and 95 kD in human keratinocyte culture media in a pattern identical to that of P1E1, a murine monoclonal antiepiligrin antibody. Comparative immunoprecipitation studies of patient sera, P1E1, and GB3 monoclonal antibody show that epiligrin is identical to the antigen (i.e., BM600 or GB3 antigen) previously reported to be absent from the skin of patients with lethal junctional epidermolysis bullosa, an inherited subepidermal blistering disease. Moreover, skin from a fetus with this disease shows no evidence of reactivity to patient antiepiligrin autoantibodies or P1E1. These studies show that antiepiligrin autoantibodies are a specific marker for a novel autoimmune blistering disease and that the epidermal basement membrane antigen absent in patients with lethal junctional epidermolysis bullosa is epiligrin.

Authors

N Domloge-Hultsch, W R Gammon, R A Briggaman, S G Gil, W G Carter, K B Yancey

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1986 Total
Citations: 1 1 2 3 4 4 4 4 1 2 6 4 2 5 4 5 6 2 4 7 4 5 5 11 9 11 21 17 26 12 12 6 1 211
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2010 (4)

Title and authors Publication Year
The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases
A Sesarman, G Vidarsson, C Sitaru
Cellular and Molecular Life Sciences 2010
Circulating IgA and IgE autoantibodies in antilaminin-332 mucous membrane pemphigoid
K Natsuga, W Nishie, S Shinkuma, R Moriuchi, M Shibata, M Nishimura, T Hashimoto, H Shimizu
British Journal of Dermatology 2010
From anti-p200 pemphigoid to anti-laminin γ1 pemphigoid
T DAINICHI, H KOGA, T TSUJI, N ISHII, B OHYAMA, A UEDA, Y NATSUAKI, T KARASHIMA, T NAKAMA, S YASUMOTO, D ZILLIKENS, T HASHIMOTO
The Journal of Dermatology 2010
Rook's Textbook of Dermatology: Burns/Rook's Textbook of Dermatology
PS Friedmann, MR Ardern-Jones, CA Holden
Rook's Textbook of Dermatology: Burns/Rook's Textbook of Dermatology 2010

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 3 patents
Referenced in 1 Wikipedia pages
Referenced in 1 clinical guideline sources
26 readers on Mendeley
See more details